Overview

• WU-CART-007 is an off-the-shelf, donor-derived CAR-T therapy engineered via CRISPR to target CD7 on malignant T cells without causing graft-versus-host disease
• The multicenter Phase I/II trial enrolled 28 adult and adolescent patients with relapsed or refractory T cell acute lymphoblastic leukemia and T cell lymphoblastic lymphoma
• At the recommended dose, 10 of 11 evaluable patients (91%) showed significant tumor reduction and eight (72.7%) achieved complete remission
• Cytokine release syndrome occurred in 88.5% of patients, predominantly mild to moderate, with rare severe cases and manageable neurotoxicity or graft-versus-host events
• A larger, global trial is now under way to confirm long-term efficacy and safety before potential regulatory approval